Edition:
United Kingdom

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

6.63USD
16 Feb 2018
Change (% chg)

$0.26 (+4.08%)
Prev Close
$6.37
Open
$6.33
Day's High
$6.65
Day's Low
$6.33
Volume
19,339
Avg. Vol
48,589
52-wk High
$8.37
52-wk Low
$3.63

Chart for

About

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting... (more)

Overall

Beta: --
Market Cap(Mil.): $204.09
Shares Outstanding(Mil.): 32.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement

* VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM

21 Dec 2017

BRIEF-vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program

* VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM

21 Dec 2017

BRIEF-VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes

* VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING

06 Dec 2017

BRIEF-vTv Therapeutics reports Q3 GAAP loss per share of $0.38

* vTv Therapeutics reports third quarter 2017 financial and operational results

01 Nov 2017

BRIEF-JDRF, VTV Therapeutics collaborate on Phase 2 study of novel treatment for type 1 diabetes

* JDRF and VTV Therapeutics announce collaboration on Phase 2 study of novel treatment for Type 1 diabetes

06 Sep 2017

Earnings vs. Estimates